Development & Commercialisation of two novel vaccines Intranasal Covid-19 Vaccine and RTS, S Malaria Vaccine | India Science, Technology & Innovation - ISTI Portal

×

Acces sibility Controls

Development & Commercialisation of two novel vaccines Intranasal Covid-19 Vaccine and RTS, S Malaria Vaccine Startup

Implementing Organization

Project Overview

Focused on developing India’s first intranasal Covid-19 vaccine and RTS, S Malaria vaccine, with a state-of-the-art facility in Bhubaneswar.

Related Research

Quick Information

Focus Area

Vaccines, Healthcare

Sanction Amount

₹ ₹311.30 Cr (TDB assistance ₹100.00 Cr)

Status

Commercialisation stage

Output

No. of Research Paper

00

Technologies (If Any)

00

No. of PhD Produced

N/A

Startup (If Any)

00

No. of Patents

Filed :00

Grant :00